The Summary
Two massive, double-blind randomized controlled trials involving 3,808 participants across 40 countries investigated whether oral semaglutide could slow cognitive decline in early-stage Alzheimer's disease. Participants with amyloid-confirmed mild cognitive impairment or mild dementia were tracked for over two years. The results showed no significant difference in clinical dementia ratings between those taking semaglutide and those taking a placebo. The trials were ultimately discontinued due to this lack of clinical benefit, confirming that oral semaglutide is not an effective treatment for slowing early Alzheimer's disease.
Why this is interesting
Previous observational studies hinted that GLP-1 drugs like semaglutide might protect the brain and reduce dementia risk, sparking hope it could treat Alzheimer's disease. However, these gold-standard trials definitively show it does not slow cognitive decline once early Alzheimer's has begun. For readers, this means while semaglutide remains highly effective for metabolic health, it is not the long-awaited silver bullet for treating Alzheimer's. The search for effective dementia therapies must continue to focus on other neurological mechanisms and targets.